Global Ulcerative Colitis Market 2016-2020 - Product Image

Global Ulcerative Colitis Market 2016-2020

  • ID: 3721883
  • Report
  • Region: Global
  • 67 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abbott
  • Avaxia Biologics
  • Genentech
  • Kaken Pharmaceutical
  • Mochida Pharmaceutical
  • Salix Pharmaceuticals
  • MORE
About Ulcerative Colitis

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that affects the colon and rectum. Inflammation and ulcers are formed in the innermost lining of the colon and rectum, resulting in the production of pus and mucous. Based on the extent of inflammation and the location, ulcerative colitis can be of different types: ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Abdominal cramps, diarrhea, and rectal bleeding are among the common symptoms observed in individuals with the disease. Medications such as 5-aminosalicylates, steroids, purine analogs, immunomodulators, and biologics are used to treat the disease.

The analysts forecast the global ulcerative colitis market to grow at a CAGR of 6.6% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global ulcerative colitis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used to treat ulcerative colitis.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Ulcerative Colitis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- Janssen Biotech
- Merck
- Takeda Pharmaceuticals

Other prominent vendors
- Abbott
- Ajinomoto Pharmaceuticals
- Amgen
- Arena Pharmaceuticals
- AstraZeneca
- Astellas Pharma
- Avaxia Biologics
- BioLineRx
- Celgene
- Cosmo Pharmaceuticals
- Eisai
- Ferring Pharmaceuticals
- Galapagos
- Genentech
- Gilead Sciences
- GlaxoSmithKline
- Hutchison Medi Pharma
- Immune Pharmaceuticals
- InDex Pharmaceuticals
- Kaken Pharmaceutical
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
- Lipid Therapeutics
- Meda
- Mitsubishi Tanabe
- Mochida Pharmaceutical
- Morphotek
- Nestlé
- Pfizer
- Procter & Gamble
- Qu Biologics
- Receptos
- Salix Pharmaceuticals
- Shield Therapeutics
- Shire Pharmaceuticals
- Sterna Biologicals
- Tillotts Pharma
- TopiVert
- UCB
- Zeria Pharmaceutical

Market drivers
- Increase in patient assistance programs
- For a full, detailed list, view the full report

Market challenges
- Patent expiries
- For a full, detailed list, view the full report

Market trends
- Rising use of biologics
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Avaxia Biologics
  • Genentech
  • Kaken Pharmaceutical
  • Mochida Pharmaceutical
  • Salix Pharmaceuticals
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Disease overview
  • Understanding the disease
  • Etiology
  • Epidemiology
  • Symptoms
  • Diagnosis and testing
  • Treatment
  • Prognosis
  • Economic burden
  • Reimbursement scenario
PART 06: Pipeline analysis
  • Z-206
  • MD-0901
  • TP05
  • Stelara
  • Etrolizumab
  • Xeljanz
  • HMPL-004
  • Kappaproct
  • AJG511
  • AJM300
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation by molecule type
  • Biologics
  • Small molecules
  • Biologics segment in ulcerative colitis drugs market
  • Small molecules segment in ulcerative colitis drugs market
PART 09: Market segmentation by dosage form
  • Solid
  • Liquid
PART 10: Market segmentation by route of administration
  • Oral
  • Parenteral
PART 11: Geographical segmentation
  • Global ulcerative colitis drugs market by geography 2015-2020
  • Ulcerative colitis drugs market in Americas
  • Ulcerative colitis drugs market in EMEA
  • Ulcerative colitis drugs market in APAC
PART 12: Market drivers
  • Increase in patient assistance programs
  • High unmet needs
  • Tentative approval of candidates in pipeline
PART 13: Impact of drivers

PART 14: Market challenges
  • High cost of drugs
  • Patent expiries
  • Adverse effects of drugs
  • Unknown disease etiology
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Growing public awareness
  • Rising use of biologics
  • Emergence of biosimilars
  • Strategic alliances
PART 17: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
  • AbbVie
  • Janssen Biotech
  • Merck
  • Takeda Pharmaceuticals
  • Other prominent vendors
PART 18: Appendix
  • List of abbreviations
PART 19: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Causes of ulcerative colitis
Exhibit 03: Symptoms of ulcerative colitis
Exhibit 04: Diagnostic approach for ulcerative colitis
Exhibit 05: Treatment options for ulcerative colitis
Exhibit 06: Treatment guidelines of ulcerative colitis based on severity
Exhibit 07: Surgical procedures to treat ulcerative colitis
Exhibit 08: Global ulcerative colitis drugs market: Pipeline portfolio
Exhibit 09: Global ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 10: Snapshot of global ulcerative colitis drugs market
Exhibit 11: Five forces analysis
Exhibit 12: Global ulcerative colitis drugs market by molecule type
Exhibit 13: Global ulcerative colitis drugs market by molecule type 2015
Exhibit 14: Biologics segment in ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 15: Small molecules segment in ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 16: Global ulcerative colitis drugs market by dosage form
Exhibit 17: Global ulcerative colitis drugs market by route of administration
Exhibit 18: Global ulcerative colitis drugs market segment by geography 2015
Exhibit 19: Ulcerative colitis drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 20: Ulcerative colitis drugs market in Americas 2015-2020 ($ billions)
Exhibit 21: Ulcerative colitis drugs market in EMEA 2015-2020 ($ billions)
Exhibit 22: Ulcerative colitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Global ulcerative colitis drugs market share analysis 2015
Exhibit 26: YoY revenue comparison of top drugs for ulcerative colitis 2011-2014 ($ millions)
Exhibit 27: AbbVie: Product segmentation by revenue 2014
Exhibit 28: AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 29: AbbVie: Geographical segmentation by revenue 2014
Exhibit 30: AbbVie: YoY growth and revenue of Humira 2012-2014 ($ billions)
Exhibit 31: AbbVie: Key takeaways
Exhibit 32: Janssen Biotech: YoY growth and revenue of Remicade 2012-2014 ($ millions)
Exhibit 33: Janssen Biotech: YoY growth and revenue of Simponi/Simponi ARIA 2012-2014 ($ millions)
Exhibit 34: Janssen Biotech: Key takeaways
Exhibit 35: Merck: Business segmentation by revenue 2014
Exhibit 36: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 37: Merck: Geographical segmentation by revenue 2014
Exhibit 38: Merck: YoY growth and revenue of Remicade 2012-2014 ($ millions)
Exhibit 39: Merck: YoY growth and revenue of Simponi 2012-2014 ($ millions)
Exhibit 40: Merck: Key takeaways
Exhibit 41: Takeda Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 42: Takeda Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 44: Takeda Pharmaceuticals: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott
  • Avaxia Biologics
  • Genentech
  • Kaken Pharmaceutical
  • Mochida Pharmaceutical
  • Salix Pharmaceuticals
  • MORE
New Report Released: – Global Ulcerative Colitis Market 2016 - 2020

The author of the report recognizes the following companies as the key players in the Global Ulcerative Colitis Market: AbbVie, Janssen Biotech, Merck, and Takeda Pharmaceuticals.

Other Prominent Vendors in the market are: Abbott, Ajinomoto Pharmaceuticals, Amgen, Arena Pharmaceuticals, AstraZeneca, Astellas Pharma, Avaxia Biologics, BioLineRx, Celgene, Cosmo Pharmaceuticals, Eisai, Ferring Pharmaceuticals, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lipid Therapeutics, Meda, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Nestlé, Pfizer, Procter & Gamble, Qu Biologics, Receptos, Salix Pharmaceuticals, Shield Therapeutics, Shire Pharmaceuticals, Sterna Biologicals, Tillotts Pharma, TopiVert, UCB, and Zeria Pharmaceutical.

Commenting on the report, an analyst from the research team said: “A noteworthy trend to watch for in the pharmaceutical industry is the rising use of biologics. Biologics, available as either intravenous or subcutaneous injections, are increasingly becoming the treatment of choice for ulcerative colitis. They act by either blocking the interleukins or the tumor necrosis factor (TNF)-alpha. Etrolizumab, being developed by Genentech (Roche), and Stelara (ustekinumab), developed by Janssen Pharmaceuticals, are prominent biologics that are under investigation for the treatment of ulcerative colitis and are expected to be launched in the market during the forecast period.”

According to the report, a key driver for market growth is the increase in patient assistance programs. Patients who cannot afford costly treatments are provided financial assistance by state and federal agencies such as Medicaid, Medicare, and Social Security in the US. People can also apply for free medications or financial co-pay assistance for the drug Humira through AbbVie's patient assistance program. According to the Humira Complete Savings Card, the drug can be obtained for as low as $5 per month. Similarly, Janssen Pharmaceuticals has initiated programs such as JanssenAccessOne and RemiStart.

Further, the report states that expiring patents for many drugs will affect the bottom line for manufacturers and in turn, have an adverse impact on market growth.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- AbbVie
- Janssen Biotech
- Merck
- Takeda Pharmaceuticals
- Abbott
- Ajinomoto Pharmaceuticals
- Amgen
- Arena Pharmaceuticals
- AstraZeneca
- Astellas Pharma
- Avaxia Biologics
- BioLineRx
- Celgene
- Cosmo Pharmaceuticals
- Eisai
- Ferring Pharmaceuticals
- Galapagos
- Genentech
- Gilead Sciences
- GlaxoSmithKline
- Hutchison Medi Pharma
- Immune Pharmaceuticals
- InDex Pharmaceuticals
- Kaken Pharmaceutical
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
- Lipid Therapeutics
- Meda
- Mitsubishi Tanabe
- Mochida Pharmaceutical
- Morphotek
- Nestlé
- Pfizer
- Procter & Gamble
- Qu Biologics
- Receptos
- Salix Pharmaceuticals
- Shield Therapeutics
- Shire Pharmaceuticals
- Sterna Biologicals
- Tillotts Pharma
- TopiVert
- UCB
- Zeria Pharmaceutical.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll